Multiple myeloma -a heterogeneous challenge
Publish place: 2nd International Personalized Medical Congress
Publish Year: 1396
نوع سند: مقاله کنفرانسی
زبان: English
View: 415
نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد
- Certificate
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
IPMCMED02_143
تاریخ نمایه سازی: 29 فروردین 1397
Abstract:
about 10% of hematological malignancies is multiple myeloma. despite relatively low incidence , ecomonic impact is high.we surely cannot treat all patients in the same way.risk stratification is mandatory and it will be influence on prognosis,clinical trial selection and therapy.with the availability of novel therapies, new markers are now more important than ever in predicting not only risk and outcome but also treatment selection.here is a short review of this heterogeneous disease and usage of personalized medicine for risk stratification and treatment modality.
Authors
Mojan Asadi
hematologist-oncologist,assistant profesor of Alborz university of medical science